Should I Buy IMA? IMA 2026 Analysis

Should You Buy ImageneBio Inc (IMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

5.000

1 Day change

-7.41%

52 Week Range

18.000

Analysis Updated At

2026/03/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ImageneBio Inc (IMA) is not a good buy for a beginner investor with a long-term strategy at this time. The stock exhibits bearish technical indicators, poor financial performance, and lacks positive catalysts or strong trading signals. Given the investor's preference for long-term growth, this stock does not align with their goals.

Technical Analysis

The technical indicators for IMA are bearish. The MACD is negatively expanding, the RSI is neutral at 27.734, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 5.863 and the current price at 5.41.

Positive Catalysts

NULL identified. No recent news or significant events to drive positive sentiment.

Neutral/Negative Catalysts

The stock has a 60% chance to decline further in the next day (-0.97%), week (-1.88%), and month (-6.58%). Additionally, the company's financial performance is deteriorating, with a significant drop in net income (-24.29% YoY) and EPS (-62.11% YoY).

Financial Performance

In Q4 2025, the company's revenue remained at 0 with no YoY growth. Net income dropped to -$6,908,000 (-24.29% YoY), and EPS declined to -0.86 (-62.11% YoY). While gross margin is at 100%, it is not indicative of profitability given the negative income and EPS trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for IMA.

3 Analyst Rating

Wall Street analysts forecast IMA stock price to rise

2 Buy

0 Hold

1 Sell

Moderate Buy

Current: 5.000

Low

Averages

High

Current: 5.000

Low

Averages

High

Wedbush

Martin Fan

Neutral -> Underperform

downgrade

$23 -> $2

AI Analysis

2025-11-25

Reason

Wedbush

Martin Fan

Price Target

$23 -> $2

AI Analysis

2025-11-25

downgrade

Neutral -> Underperform

Reason

Wedbush analyst Martin Fan downgraded ImageneBio to Underperform from Neutral with a price target of $2, down from $23, while assuming coverage of the stock. The firm recommends investors avoid ImageneBio shares unless the company either gains a development partner, or shifts its focus to a new indication, citing high development costs, the company's reliance on a single asset and indication, a limited catalyst calendar, and what it views as competitors with equivalent or superior product profiles.

Leerink

Outperform

initiated

$30

2025-10-24

Reason

Leerink

Price Target

$30

2025-10-24

initiated

Outperform

Reason

Leerink initiated coverage of ImageneBio (IMA) with an Outperform rating and $30 price target. The firm views shares as "dramatically undervalued," particularly following a selloff in the wake of disappointing competitor Sanofy's (SNY) amlitelimab results on September 4. Leerink believes ImageneBio's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is a potential blockbuster for atopic dermatitis. Early clinical data for IMG-007 suggests compelling efficacy at Week 16 compared to Dupixent. Competing drug candidate Phase 3 disappointments from Amgen's (AMGN) OX40 rocatinlimab and Sanofi's OX40L amlitelimab have dampened investor sentiment toward the OX40-OX40L class. This yields a favorable setup for IMG-007 to deliver a superior "trifecta" competitive profile, the firm argues.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMA

Unlock Now

IMA Should I Buy

IMA Should I Buy

Should You Buy ImageneBio Inc (IMA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch